comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 21:28:13 - browse：19726

Illustration of a doctor and patient. The shadow behind the doctor displays 0s and 1s for artificial intelligence. –– health tech coverage from STAT — Molly Ferguson for STAT

The world’s largest technology companies are racing to build generative AI into every corner of health and medicine.

Microsoft has formed an alliance with the electronic health records vendor Epic to wire the technology into dozens of health software products. Google is infusing it into tools used by hospitals to collect and organize data on millions of patients. Not to be outdone, Amazon has unveiled a service to help build clinical note scribes, and is separately working to embed generative AI in drug research and development.

All of this has unfolded faster than federal regulators could blink — or answer questions about how the technology should be tested and evaluated, whether it will help or hurt patients, and how it will impact privacy and the use of personal data.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The SUPPORT Act is critical to fighting the opioid crisis

focus

WSS

Making AI in medicine accessible to smaller, and rural hospitals

Readout LOUD podcast: What to know about H5N1 bird flu

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

H5N1 bird flu: what we're starting to learn about infection in cows

How to improve immunocompromised access to mAb treatments

Study: AI not yet building 'n

focus

comprehensive

explore

Cancer drug shortages should be causing more outrage

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Duchenne breakthrough therapy leaves behind pioneering families

How I ended up pumping milk in a bathroom stall at JPM 2024

Medical leaders decry Supreme Court decision on affirmative action

Biotech reporter’s notebook: A sunnier mood at JPM 2024

BioMarin wins approval for gene therapy to treat hemophilia A

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

explore

HHS names first

Researchers on aging grapple with how to calculate biological age

How to improve immunocompromised access to mAb treatments

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

As JPM 2024 winds down, some health tech firms project optimism

Study: AI not yet building 'n

hotspot

focus

hotspot

explore